This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourcedmust be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page.
This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles
Schinazi's contribution to the discovery of sofosbuvir is contentious. He is the co-author of a 2005 paper that discovered a precursor to the drug.[1] Jean-Pierre Sommadossi, a principal founder of Idenix and a co-founder of Pharmasset, has stated that Schinazi “wasn't involved with anything” in the actual development of sofosbuvir. Schinazi's former business partner no longer speaks to him.[1][2]
Previous material violates Wikipedia Policy. The point of view was not neutral and the statements are not well sourced. One statement is merely opinion. Selected fragments of source material have been taken and are presented in a contentious manner to disparage. Other non-disparaging source material was not provided.
References
^ abCite error: The named reference :0 was invoked but never defined (see the help page).
